ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TECENTRIQ
Bladder, kidney, and other urologic cancers
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TECENTRIQ Rx

Generic Name and Formulations:
Atezolizumab 60mg/mL; soln for IV infusion after dilution; preservative-free.

Company:
Genentech, Inc.

Therapeutic Use:

Indications for TECENTRIQ:

Locally advanced or metastatic urothelial carcinoma in patients who: are ineligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥5% of tumor area), as determined by an FDA-approved test; are ineligible for any platinum-containing chemotherapy regardless of PD-L1 status; or have disease progression during or following any platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant chemotherapy.

Adult:

Give as IV infusion over 60mins. 1200mg every 3 weeks until disease progression or unacceptable toxicity. May give subsequent infusions over 30mins if first infusion tolerated. Dose modifications: see full labeling. Administer corticosteroids for most Grade ≥2 related immune-mediated reactions.

Children:

Not established.

Warnings/Precautions:

Monitor for immune-mediated pneumonitis, hepatitis (monitor LFTs), diarrhea or colitis, endocrinopathies (eg, hypophysitis, thyroid disorders, adrenal insufficiency, diabetes), other immune-mediated reactions (eg, myocarditis, pancreatitis, encephalitis, serious skin reactions). Permanently discontinue for Grade 3 or 4 pneumonitis, AST or ALT >8×ULN or total bilirubin >3×ULN, Grade 4 diarrhea or colitis, Grade 4 other immune-mediated reactions, persistent Grade 2 or 3 reactions (except endocrinopathies) that do not recover to Grade 0–1 within 12wks after last dose, inability to reduce corticosteroid dose to ≤10mg/day of prednisone or equivalent within 12wks after last dose, or recurrent Grade 3 or 4 reactions. Withhold for Grade 2 pneumonitis, AST or ALT >3–8×ULN or total bilirubin >1.5–3×ULN, Grade 2 or 3 diarrhea or colitis, Grade 2–4 endocrinopathies, Grade 3 other immune-mediated reactions; may be resumed when recover to Grade 0–1 and steroid dose ≤10mg/day of prednisone or equivalent. Monitor for signs/symptoms of infection; withhold if Grade 3 or 4 until resolved. Monitor for infusion-related reactions; permanently discontinue if Grade 3 or 4 develops; interrupt or slow the infusion rate if Grade 1 or 2 (consider premedications with subsequent doses). Evaluate for Vogt-Koyanagi-Harada syndrome if uveitis combined with other immune-mediated reactions occur. Embryo-fetal toxicity. Pregnancy; exclude status before initiation. Females of reproductive potential should use effective contraception during and for ≥5 months after final dose. Nursing mothers: not recommended (during and for ≥5 months after final dose).

Pharmacological Class:

Programmed death-ligand 1 (PD-L1) blocking antibody.

Adverse Reactions:

Fatigue, decreased appetite, nausea, constipation, urinary tract infection, diarrhea, pyrexia, dyspnea, cough; immune-mediated reactions, lab abnormalities. Combination therapy: also alopecia, arthralgia, hypertension, peripheral neuropathy.

Generic Availability:

NO

How Supplied:

Single-dose vial (20mL)—1

Indications for TECENTRIQ:

First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumor aberrations, in combination with bevacizumab, paclitaxel, and carboplatin. Metastatic NSCLC in patients with disease progression during or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Tecentriq.

Adult:

Give as IV infusion over 60mins; may give subsequent infusions over 30mins if first infusion tolerated. Previously treated: 1200mg every 3 weeks until disease progression or unacceptable toxicity. First-line therapy: 1200mg followed by bevacizumab, paclitaxel, and carboplatin on Day 1 of each 21-day cycle for max 4–6 cycles of chemotherapy; then 1200mg followed by bevacizumab on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Dose modifications: see full labeling. Administer corticosteroids for most Grade ≥2 related immune-mediated reactions.

Children:

Not established.

Warnings/Precautions:

Monitor for immune-mediated pneumonitis, hepatitis (monitor LFTs), diarrhea or colitis, endocrinopathies (eg, hypophysitis, thyroid disorders, adrenal insufficiency, diabetes), other immune-mediated reactions (eg, myocarditis, pancreatitis, encephalitis, serious skin reactions). Permanently discontinue for Grade 3 or 4 pneumonitis, AST or ALT >8×ULN or total bilirubin >3×ULN, Grade 4 diarrhea or colitis, Grade 4 other immune-mediated reactions, persistent Grade 2 or 3 reactions (except endocrinopathies) that do not recover to Grade 0–1 within 12wks after last dose, inability to reduce corticosteroid dose to ≤10mg/day of prednisone or equivalent within 12wks after last dose, or recurrent Grade 3 or 4 reactions. Withhold for Grade 2 pneumonitis, AST or ALT >3–8×ULN or total bilirubin >1.5–3×ULN, Grade 2 or 3 diarrhea or colitis, Grade 2–4 endocrinopathies, Grade 3 other immune-mediated reactions; may be resumed when recover to Grade 0–1 and steroid dose ≤10mg/day of prednisone or equivalent. Monitor for signs/symptoms of infection; withhold if Grade 3 or 4 until resolved. Monitor for infusion-related reactions; permanently discontinue if Grade 3 or 4 develops; interrupt or slow the infusion rate if Grade 1 or 2 (consider premedications with subsequent doses). Evaluate for Vogt-Koyanagi-Harada syndrome if uveitis combined with other immune-mediated reactions occur. Embryo-fetal toxicity. Pregnancy; exclude status before initiation. Females of reproductive potential should use effective contraception during and for ≥5 months after final dose. Nursing mothers: not recommended (during and for ≥5 months after final dose).

Pharmacological Class:

Programmed death-ligand 1 (PD-L1) blocking antibody.

Adverse Reactions:

Fatigue, decreased appetite, nausea, constipation, urinary tract infection, diarrhea, pyrexia, dyspnea, cough; immune-mediated reactions, lab abnormalities. Combination therapy: also alopecia, arthralgia, hypertension, peripheral neuropathy.

Generic Availability:

NO

How Supplied:

Single-dose vial (20mL)—1

Sign Up for Free e-Newsletters